Abstract: Vaccine development for Group A streptococcal (GAS) infection has been extensively focused on the N-terminal hypervariable or the C-terminal conserved regions 18 of the M protein, a major virulence factor of GAS. We evaluated the immunogenicity and functional activity of the conserved C-terminal peptide vaccine candidate, J8, conjugated 20 to CRM197, in two mouse strains: C3H (H2 k ) and Balb/c (H2 d ), and in Rhesus macaques. Mice were immunized with J8-CRM197 formulated with Amorphous Aluminum 22
Introduction
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Group A Streptococcus (GAS) remains a leading cause of several diseases with global impact, ranging from mild (pharyngitis and impetigo) to invasive (cellulitis, 4 bacteremia, pneumonia, necrotizing fasciitis and streptococcal toxic shock syndrome) infections, as well as non suppurative sequelae (acute rheumatic fever and post-6 streptococcal glomerulonephritis) which are prominent in developing countries 1 . M protein has been described as the major surface-expressed virulence factor and the 8 determinant of naturally acquired immunity against GAS 2, 3 . Until recently, M protein has been the major focus of vaccine design, and two strategies targeting this antigen have 10 been extensively studied. The most advanced work to date has focused on the highly immunogenic but hypervariable N-terminal region of M protein as the basis for a multi-12 epitopic vaccine approach. A 26-valent vaccine has been evaluated in human clinical trials and demonstrated to induce opsonic antibodies to several representative GAS 14 serotypes 4 . However, the utility of such an approach has been questioned since serotype distribution of strains causing disease differs based upon geographical region studied and 16 is complex and poorly understood in many parts of the world where vaccines would be of the greatest benefit; however, inclusion of representative N-terminal epitopes for specific 18 geographical locations may be one approach to overcome these restrictions [5] [6] [7] [8] . A second approach is based on the more highly conserved C-terminal region of the M protein [9] [10] [11] .
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This approach is expected to be advantageous since sequence conservation would imply broader strain coverage with fewer vaccine components; although, safety concerns exist 22 since this region of the protein has been shown to induce T cell responses that are cross reactive with human cardiac myosin 12 . Good et al. defined a peptide sequence (p145) 24 located in this region, which was recognized by antibodies in the sera of most adults living in areas of endemic streptococcal disease 11, 13 . A minimal B cell epitope and non-26 host reactive peptide derived from p145, termed J8, has been shown to be immunogenic and protective in mice, either administered as a peptide alone formulated with Freund's 28 adjuvant in B10.BR (H2 k ) mice 14 or conjugated to Diphtheria Toxoid (DT) and formulated on an aluminum phosphate adjuvant 15, 16 . 30 Here we describe conjugation of J8 to an alternate protein carrier, CRM197, a nontoxic analog of DT which has been used as the basis for multiple bacterial polysaccharide 32 conjugate vaccines 17 . We show that J8-CRM197 is immunogenic in inbred mice from two genetic backgrounds, H2 k elicited after a single dose of vaccine and a subsequent 10-fold increase in titer following the second dose. No further increase in titer was observed after the third immunization 8 (Fig. 1A) . No significant difference in response to the vaccine was observed between these genetically distinct inbred mice. (p = 0.8). We next performed a dose-ranging study 10 by immunizing a smaller cohort of Balb/c mice (n=3) with 12.5, 5, 1 or 0.1 µg of J8 peptide conjugated to CRM197. We observed no differences in J8-specific antibody titers 12 across all four doses (Fig. 1B) , although there was a trend towards lower antibody responses at the 0.1 µg dose. No J8-specific antibodies were detected in control animals 14 immunized with CRM197/AAHSA or Saline/AAHSA (data not shown). J8-specific antibodies bind to M-protein on the GAS surface. We examined 16 the ability of antibodies elicited by immunization of mice with J8-CRM197 to recognize the corresponding M protein epitope on intact bacterial cells. We evaluated binding of 18 J8-CRM197/AAHSA, CRM197/AAHSA, and AAHSA immune serum to four different GAS serotypes (M1, M3, M6 and M97) and found that of the groups tested, the only 20 serum that contained antibodies which bound to the surface of GAS was from mice immunized with J8-CRM197/AAHSA. One representative experiment using serotype 22 M3, is shown in Figure 2 . Similar results were obtained with other GAS serotypes (data not shown).
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J8-CRM197 mouse antibodies have opsonophagocytic activity. The functional activity of antibodies raised by immunization of mice with J8-CRM197 was evaluated in 26 an opsonophagocytic assay using GAS 88/30 M97. Naïve mouse serum was tested in the same experiments to serve as a non-immune control for determination of percent 28 opsonization. Results from four different immunization experiments are shown in Figure  3 ; two using Balb/c mice (Experiment-1 and Experiment-2), and two using C3H mice 30 (Experiment-3 and Experiment-4). From each of the four experiments only J8-CRM197/AAHSA immune serum promoted killing of the bacteria (activity ranging from 32 57-93%) which was statistically significant compared to the negative controls (CRM197/AAHSA or AAHSA immune serum [P<0.001]) (Fig. 3) . Serum from mice 34 immunized with GASM97 was used as a positive control and in all experiments caused between 90-100% killing (Data not shown).
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Immunization with J8-CRM197 induces limited protection in mice following systemic and intranasal challenge. Groups of Balb/c and C3H mice were immunized 38 with J8-CRM197/AAHSA, CRM197/AAHSA, AAHSA, heat-killed GAS M1, or recombinant M protein (strain M3). Balb/c mice were challenged (i.p) with GAS pM1 SR 40 in mucin. Ninety percent of the J8-CRM197/AAHSA immunized group and 100% of the heat-killed M1 immunized groups (positive control) survived challenge (P = 0.0001 42 relative to CRM197/AAHSA and AAHSA groups) (Fig. 4A) . In order to demonstrate protection in a second model system, C3H mice were challenged (i.n) with a GAS M3 SR 44 strain. Seventy percent of the J8-CRM197/AAHSA immunized group and 100% of the recombinant M protein immunized group (positive control) were protected from 46 challenge, while 60% of the CRM197/MAA group also survived challenge (P = 0.001 relative to the AAHSA group) (Fig. 4B) . 2 J8-CRM197 is immunogenic in non-human primates. We evaluated immunogenicity of J8-CRM197 formulated with three adjuvant combinations, AAHSA, 4 ISCOMATRIX adjuvant, and AAHSA + ISCOMATRIX adjuvant, in rhesus macaques. Figure 5 shows the time course of the antibody responses to J8 as determined by ELISA. 6
Pre-immune sera were tested as pooled samples while post-immunization titers were assessed from individual animals. IgG titers were lowest overall in animals immunized 8 with J8-CRM197/AAHSA with titers of only ~6,000 and ~9,000 following one and two doses of conjugate, respectively. In contrast, J8-CRM197 formulated in ISCOMATRIX 10 adjuvant alone or with an AAHSA/ISCOMATRIX adjuvant mixture induced IgG titers of > 20,000 after a single dose and >60,000 following a second dose. Moreover, the post-12 dose two titers were sustained after a third dose. J8-specific IgG titers were statistically significantly different (P < 0.05) between groups immunized with J8-CRM197/AAHSA-14 ISCOMATRIX adjuvant or J8-CRM197/ISCOMATRIX adjuvant vs. the group immunized with J8-CRM197/AAHSA at both post-dose two and post-dose three time 16 points. We attempted to evaluate sera from NHPs in both the OPK and IFA assays; unfortunately the pre-immune sera contained high levels of background antibodies that 18 led to both high killing activity in the OPK as well as background fluorescence in the IFA which made the data very difficult to interpret. 20 An efficacious vaccine for prevention of Group A streptococcal infection would be an important tool for reducing rheumatic fever and rheumatic heart disease in the developing 4 world as well as for reducing recurrent pharyngitis in both the developing and developed world 18 . Recent reports detailing an increase in global expansion of macrolide resistant 6 strains of Streptococcus pyogenes adds further impetus to the desire to develop such a vaccine 19, 20 . Although S. pyogenes is susceptible to penicillin, macrolides are the 8 antibiotics of choice for individuals who are allergic to β-lactams
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. M-protein, the major surface protein of GAS, is a coiled-coil protein composed of a 10 highly variable N-terminal region, which is the focus of serotyping (M typing) and genotyping (emm typing), A-repeat and B-repeat domains which do not induce opsonic 12 antibodies
22
, and a C-repeat domain, which is the most conserved of the three repeat regions and contains the J8 peptide. Previously described vaccine approaches utilizing the 14 M protein conserved C-repeat region include: (1) a recombinant protein domain encompassing the C-terminal region of strain M6 9 ; (2) selected B and T cell epitopes 16 from strain M5 presented as either synthetic peptides or recombinant protein 23 ; and (3) the 12-amino acid minimal B cell epitope J8 presented as a synthetic peptide 15 . Murine 18 studies evaluating J8 conjugated to DT and formulated with aluminum hydroxide established that this potential vaccine candidate induced opsonic antibodies which were 20 protective in a lethal challenge model 24, 25 . The objectives of the current study were, first to assess the immunogenicity and 22
protective efficacy in mice of a vaccine candidate consisting of the J8 peptide covalently conjugated to the non-toxic DT analog, CRM197, and secondly to demonstrate that 24 immunogenicity of this vaccine candidate was extendable to non-human primates. The use of CRM197 as an alternate carrier protein to Diphtheria toxin offers several potential 26 advantages in terms of vaccine manufacturability and safety. CRM197 is a component of several licensed vaccines including PREVNAR7®, PREVNAR13®, and HibTITER®
17
.
28
As such, protocols for cGMP supply and release of the protein have been established. Importantly, a substantial safety profile for use of this protein as a carrier for bacterial 30 polysaccharides has been established in humans, including infants. It is reasonable to expect that this safety profile would extend to its use as a carrier for peptide vaccine 32 antigens as well. CRM197 has been evaluated pre-clinically for additional investigational conjugate vaccines including studies with GAS polysaccharides 26 .
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J8-CRM197 formulated with AAHSA was shown to be highly immunogenic in Balb/c (H2 d ) and C3H (H2 k ) mice at a peptide dose as low as 0.1 µg, however we choose 36 the 12.5µg dose since opsonophagocytic (OPK) activity was reduced at lower doses (data not shown). Antibodies elicited by immunization with J8-CRM197/AAHSA bound to the 38 surface of four different GAS strains (M1, M3, M6 and M97), confirming that the J8 epitope is conserved across these strains as well as demonstrating that the conjugation 40 chemistry employed here does not compromise presentation of the J8 epitope. Furthermore, we demonstrated that J8-CRM197/AAHSA induces functional antibodies 42 which mediate opsonophagocytosis of GAS 88/30 M97 in vitro and lead to killing of bacteria by human phagocytic cells, a major pathway for bacterial clearance. 44
Unfortunately, we were unable to expand upon this opsonophagocytosis data with additional serotypes of GAS as suitable human blood donors for phagocytic cells could 46 not be identified for these types. This is likely due to the fact that most adults have been exposed to multiple GAS serotypes through their life and therefore have pre-existing M-2 protein based immunity. The opsonic activity of J8-CRM197 immune serum in four different mouse immunization experiments (two using Balb/c mice and two using C3H 4 mice), ranged from 53% to 97%, but no opsonic activity was observed in the sera of control animals immunized with CRM197 or adjuvant alone. 6 J8-CRM197/AAHSA induced protective immunity in mice against two serotypes of GAS in two separate challenge models suggesting that protection mediated by this 8 vaccine is not restricted to a single M-type, but rather may be broadly effective. In a systemic challenge study performed with GAS pM1 SR in Balb/c mice, the bacteria were 10 mixed with mucin in order to decrease the bacterial dose required for lethality in the model as observed in experiments with other bacterial pathogens 27 , 90% of J8-12 CRM197/AAHSA immunized animals were protected, while CRM197/AAHSA and AAHSA immunized mice did not survive. This study was repeated a total of three times, 14 and J8-CRM197/AAHSA immunized mice were protected in two out of three experiments. In an intranasal challenge study performed with GAS M3 SR in C3H mice, 16 70% of J8-CRM197/AAHSA immunized mice were protected, in contrast to 10% survival observed in mice immunized with AAHSA alone. Unexpectedly, 60% of 18 animals immunized with CRM197/AAHSA also survived. It has been previously reported that DT formulated with adjuvant also induced non-specific protection 15 . We 20 attempted to overcome this issue by increasing the time between the last immunization and subsequent bacterial challenge; however some experiments continued to show non-22 specific protection by the CRM197 conjugate control (data not shown). This study was repeated a total of five times, and J8-CRM197/AAHSA immunized mice were protected 24 in three of the experiments. However, since significant protection was not obtained in 100% of either the i.p. or i.n. challenge studies, the results of the mouse challenge models 26 must be interpreted with caution. Since mouse models of infection for many bacterial pathogens can be quite variable, and GAS is not a natural mouse pathogen, non-human 28
primates may serve as a more relevant model system for pre-clinical GAS vaccine evaluation 28 .
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It has been previously suggested that antibodies generated by immunization with the C-terminal region of GAS M protein exhibit cross-reactive binding to human serum 32 albumin (HSA), and, therefore, are not expected to exhibit any specific functional activity 29 . Our data showing opsonophagocytic activity of J8-directed antibodies appears to 34 contradict this assumption. Additionally, we performed ELISA assays to directly assess binding of sera from J8-immunized animals to HSA, and we failed to detect any binding 36 even at antigen coating concentrations as high as 10 µg/ml (data not shown). This suggests that the J8 epitope is located outside of the HSA binding site localized to the C-38 terminal portion of M protein. Alternatively, J8 may form a portion of the HSA binding site, but binding to HSA is insufficient to abolish its specific opsonophagocytic activity. 40
To our knowledge, the current study describes for the first time immunogenicity of the J8 peptide conjugated to CRM197 in mice and non human primates. J8-CRM197 42 formulated on any of the three adjuvants tested in rhesus macaques was well-tolerated and no adverse effects were observed in any vaccinated animals throughout the time 44 course of the study. All vaccinees sero-converted following a single immunization with 10 µg of J8-CRM197 conjugate, achieving serum IgG titers of 6,000 to 20,000. 46
Following a second administration, titers rose to > 65,000 in animals immunized with J8-CRM197/ISCOMATRIX adjuvant or J8-CRM197/AAHSA/ISCOMATRIX adjuvant. 2
Interestingly, animals immunized with J8-CRM197/AAHSA elicited lower IgG titers of ~10,000 after the second dose. Statistical comparisons indicated that the saponin-based 4 ISCOMATRIX adjuvant is significantly more potent than AAHSA in non-human primates. No additional enhancement in IgG levels was observed in any group following 6 a third immunization, suggesting that further enhancement will require additional evaluation of adjuvant, dose and immunization regimens. Our data demonstrating robust 8 immunogenicity of J8-CRM197 formulated with ISCOMATRIX adjuvant in non human primates establishes this immunogen as a viable vaccine candidate for further 10 optimization and testing by itself or combined with other GAS antigens. We were unable to evaluate the functional activity of these sera due to high pre-existing antibodies to 12 GAS in non-human primates. This may be due to previous exposure of the animals to this organism as has been described 30, 31 . Synthesis of J8 peptide. The peptide (Ac-Gln-Ala-Glu-Asp-Lys-Val-Lys-GlnSer-Arg-Glu-Ala-Lys-Lys-Gln-Val-Glu-Lys-Ala-Leu-Lys-Gln-Leu-Glu-Asp-Lys-Val-8
Gln-Aha-Cys-NH 2 , Aha= 6-aminohexanoic acid, MW=3541.1) was prepared by standard solid-phase peptide synthesis with Fmoc/t-Bu chemistry. The N-terminus was acetylated 10 and the C-terminus was amidated. Briefly, the peptide was synthesized by solid phase chemistry on a NovaPEG Rink Amide resin (0.62 mmeq/g, EMD Biosciences) using a 12
Symphony Synthesizer (Protein Technologies, Inc). Acylations were performed with double couplings for 30 min with a 5-fold excess of amino acids activated with equimolar 14 amounts of HBTU [2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] and HOBt (N-hydroxybenzotriazole), and a 2-fold molar excess of 16 DIEA (N,N-diisopropylethylamine). At the end of the assembly, the peptide was acetylated by treatment with a 10-fold molar excess of acetic anhydride. The dry peptide 18 resin was then treated with cleavage mixture (82.5% trifluoroacetic acid, 5% phenol, 5% thioanisole, 5% water, 2.5% ethanedithiol) for 2h at room temperature. The filtered 20 peptide solution was precipitated with cold diethyl ether, isolated by centrifugation, washed twice with cold diethyl ether, dried, resuspended, and lyophilized. The peptide 22 was purified by Reverse Phase HPLC on a C18 Jupiter Column (Phenomenex Jupiter 10µ, C18, 300A) and eluted with an appropriate linear gradient of an increasing 24 concentration of acetonitrile containing 0.1% TFA. The purified peptide was characterized by electrospray mass spectrometry. 26
Synthesis of biotinylated J8 peptide. The peptide (Ac-Gln-Ala-Glu-Asp-LysVal-Lys-Gln-Ser-Arg-Glu-Ala-Lys-Lys-Gln-Val-Glu-Lys-Ala-Leu-Lys-Gln-Leu-Glu-28
Asp-Lys-Val-Gln-Aha-Cys (PEG-Biotin)-NH 2 , Aha= 6-aminohexanoic acid, PEG= polyethylene glycol, MW=4066.8) was prepared by a reaction of purified J8 peptide with 30 a 2-fold molar excess of EZ-Link maleimide-PEG2-Biotin (Thermo Fisher Scientific, Rockford, IL) in 0.1M ammonium acetate buffer, pH 7.0 for 1 hour. The peptide was 32 purified by Reverse Phase HPLC on a C18 Jupiter Column (Phenomenex Jupiter 10µ, C18, 300A) and eluted with an appropriate linear gradient of an increasing concentration 34 of acetonitrile containing 0.1% TFA. The purified peptide was characterized by electrospray mass spectrometry. 36
Preparation of J8-CRM197 conjugate. Purified CRM197 carrier protein was obtained from Merck Research Laboratories (West Point, PA) and activated for 38 conjugation by addition of maleimide groups to surface-accessible lysine residues using the heterobifunctional cross-linking reagent succinimidyl-4-(N-40 maleimidomethyl)cyclohexane-1-carboxylate (SMCC, Thermo Fisher Scientific, Rockford, IL) 32 . Briefly, a concentrated stock of CRM197 in phosphate buffer was 42 diluted in 20mM HEPES, 0.15M NaCl, 0.005M EDTA, pH 7.3 to a total protein concentration of 1 mg/ml. Nine mg of SMCC (10-fold molar ratio to theoretical 44 CRM197 lysine content) was dissolved in 1 ml of dry dimethyl sulfoxide (DMSO) and added to the CRM197 solution while it was being gently vortexed. The reaction mixture 46 was incubated in the dark at room temperature for 3 hours. The sample was then reduced in volume to 5 ml using an Amicon Ultra 4 centrifugal concentrator and desalted over a 2 Hi Prep 26/10 desalting column (GE Healthcare Life Sciences) equilibrated in 20mM HEPES, 0.15M NaCl, 5mM EDTA, pH 7.3. The amount of maleimide incorporated into 4 the CRM197 was determined using a 5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB) -based assay which relies upon the consumption of a fixed amount of N-acetyl cysteine from a 6 standard solution. CRM197 total protein was determined by the bicinchoninic acid (BCA) protein assay. Conjugation of thiolated J8 peptide to maleimide-activated 8 CRM197 was performed at a 2 to1 molar ratio of peptide thiol to CRM197 maleimide. The required amount of thiolated J8 peptide was weighed out and placed in a 20 ml glass 10 vial to which the activated CRM197 solution was added. The solution was mixed to ensure that the peptide was completely dissolved and then incubated overnight at room 12 temperature. The conjugate was purified of un-reacted peptide by size exclusion chromatography over a 2. Research Center (NIRC, Lafayette, LA). A group of 12 rhesus macaques were included in the study. Selected animals were matched by age, sex and weight, housed in social 42 settings and randomly assigned to three experimental groups of four individuals each that received different vaccine formulations. Four monkeys per group were immunized i.m 44 with J8-CRM197 with various adjuvant formulations. Monkeys received a vaccine dose on days 0, 56 and 112. Vaccine antigen/adjuvant concentrations were: 20 µg/ml of J8 46 peptide formulated with AAHSA (450 µg/ml) and/or ISCOMATRIX™ (120 µg/ml). A vaccine dose of 0.5 ml was injected per animal. Serum samples were collected on days 0 2 (pre-immunization), 28, 56, 70, 84, 126 and 140. Only samples collected on days 0, and weeks 4, 10 and 20 were tested in ELISA. 4
Bacterial strains and culture conditions. For bacterial designations, M type and origin see Table 1 . All the previously mentioned strains and a GAS serotype M6-12348 6 obtained from ATCC were grown in Todd Hewitt broth (THB) (Becton Dickinson) overnight and processed for use in immunofluorescence or bactericidal assays. 8 ELISA assays. Immulon 2 HB (Thermo Labsystems, Catalog # 3455) 96 well plates coated with J8 peptide were used for testing mouse sera samples and Neutravidin 10 (Pierce, Cat # 15129) 96-well plates coated with biotinylated J8 were used to test nonhuman primate sera samples. In both experiments the plates were coated with 0. three times with PBS for 10 min. Mounting solution was added and stained bacteria were visualized at 100X magnification using a fluorescence microscope. 42
Whole Blood Bactericidal Assay. Murine antibodies were assayed for opsonic activity against GAS M97 as previously described 3, 25, 36 . Briefly, GAS were incubated 44 end-over-end rotation at 37 o C for 3h in the presence of non opsonic human blood and either mouse immune or control naïve mouse sera. Antisera to heat killed GAS strain 46 M97 was used as a positive control. Bacteria were plated in triplicate on sheep blood agar plates (Remel, Cat # 01202) and colony forming units (cfu) were counted after 24h 2 incubation. The percentage of bacteria killed was determined using the following equation: [(mean cfu negative control )-(mean cfu test sample )/mean cfu negative control ] x 100. 4
Challenge experiments. Mice were challenged 50-55 days after the primary immunization regimen. Both the pM1 and M3 strains used for challenge experiments had 6 been serially passaged in mouse spleen to enhance virulence and made streptomycin resistant (SR) 25 , then labeled (pM1 SR) and (M3 SR) 8
For systemic challenge: the pM1 SR strain was grown overnight in 10 ml aliquots of THBN. The cultures were combined and bacteria were collected by centrifugation at 10 3000 rpm for 10 minutes, the pellet was resuspended in cold THBN and serially diluted, cfu were determined by plating on sheep blood agar and the undiluted culture was held at 12 4 o C overnight. The following day, the culture was resuspended to 1x10 8 cfu/ml in THBN, then serially diluted in THBN plus 5% mucin type II (Sigma, St. Louis, MO). The 1x10 5 14 cfu/ml dilution was further diluted to the inoculum challenge dose of 7.5x10 3 cfu/ml in mucin and injected intraperitoneally (i.p) into Balb/c mice at 0.4 ml/mouse. The mice 16
were observed daily for survival for 15 days. Inoculum concentration was confirmed by plating on blood agar plates. 18 For intranasal (i.n) challenge: 48 hours before challenge, mice were given streptomycin (200 µg/ml) in their drinking water. This strain was grown as described 20 previously 37 . Briefly, a frozen stock of GAS M3 SR was cultured overnight in THB supplemented with 0.5% yeast extract (THYE) containing 200 µg/ml streptomycin 22 (Teknova, Cat # S6550) at 37°C in 5% CO 2 . The overnight culture was subcultured and grown for 4.5 h at 37°C with 5% CO 2 to an A 600 between 0.9 and 1.0. The bacteria were 24 collected by centrifugation, washed and resuspended in THYE containing 25% glycerol (final concentration) and frozen at -70°C. The concentration of viable bacteria (~1.7x10 9 26 cfu/ml), was confirmed by plating on sheep blood agar plates containing streptomycin (Teknova, Cat # B0143). On the day of the challenge the frozen GAS M3 SR was 28 thawed and used undiluted (~1.7x10 9 cfu/ml). The mice were sedated with 100mg/kg ketamine (Fort Dodge Animal Health) and 10mg/kg xylazine (AnaSed®) injected 30 intraperitoneally. The bacterial suspension (15 µl/nare) was administered to the sedated mice. The mice were observed daily for survival for 15 days. (fluorescein isothiocyanate) -stained group A streptococci (GAS, serotype M3) viewed under the same conditions, using a microscope with a 100X objective. Bacteria were 12 stained with pre-immune mouse sera (A), CRM197 immune serum (B), J8-CRM197 immune serum (C) and type M3 immune serum as positive control (D). All sera were 14 taken after the last boost and diluted 1:50. 16 Figure 3 . Average percent opsonization of GAS M97 strain by sera taken one week after the last boost (Day 50). Filled symbols (•▲) represent two independent experiments 18 using mouse sera taken from C3H immunized mice and open symbols (○∆) represent two independent experiments using sera taken from Balb/c mice. In all four experiments only 20 J8-CRM197/AAHSA immune serum promoted killing of the bacteria (activity ranging from 57-93%) which was statistically significant compared to the negative controls 22 (CRM197/AAHSA or AAHSA) immune serum p <0.001. 
